Calcium Channel Blockers in Current Medical Practice: An Update for 1993

References

• Brittinger WD, Schwarzbeck A, Wittenmeier KW, Twittenhoff WD, Stegaru B, Huber W, Ewald RW, von Henning GE, Fabricus M, Strauch M. Klinisch-experimentelle Untersuchungen über die blutdrucksenkende Wirkung von Verapamil. Deutsch Med Wschr 1970; 95: 1871–1877
   PubMedGoogle Scholar
• Bender F. Die Behandlung der tachykarden Arrhythmien und der arteriellen Hypertonie mit Verapamil. Arzn Forsch (Drug Res) 1970; 20: 1310–1316
   PubMed Web of Science ®Google Scholar
• Belz GG. Die Wirkung des Gallopamil auf den Blutdruck des Menschen bei oraler Medikation im akuten Versuch. Arzn Forsch (Drug Res) 1970; 20: 799–802
   PubMedGoogle Scholar
• Slish DF, Schultz D, Schwartz A. Molecular biology of the calcium antagonist receptor. Hypertension 1992; 19: 19–24
   PubMed Web of Science ®Google Scholar
• Catterall WA, Striessnig J. Receptor sites for Ca2+channel antagonists. Trends Pharmacol Sci 1992; 13: 256–262
   PubMed Web of Science ®Google Scholar
• Kelly JG, Omalley K. Clinical pharmacokinetics of calcium antagonists. Clin Pharmacokinet 1992; 22: 416–433
   PubMed Web of Science ®Google Scholar
• Kirch W, Kleinbloesem CH, Belz G G. Drug interactions with calcium antagonists. Pharmac Ther 1990; 45: 109–136
   PubMed Web of Science ®Google Scholar
• Bailey DG, Spence JD, Munoz C, Arnold J MO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268–269
   PubMed Web of Science ®Google Scholar
• Ellis JS, Seymour RA, Monkman SC, Idle J R. Gingival sequestration of nifedipine in nifedipine-induced gingival overgrowth. Lancet 1992; 339: 1382–1383
   PubMed Web of Science ®Google Scholar
• Slonim A, Cristal N. Cardiovascular diseases, blood rheology, and dihydropyridine calcium antagonists. J Cardiovasc Pharmacol 1992; 19(Suppl 3)S96–S98
   PubMedGoogle Scholar
• Fetkovska N. platelet activation by low-density lipoprotein and serotinin: effects of calcium antagonists. J Cardiovasc Pharmacol 1992; 19(Suppl 3)S25–S28
   PubMedGoogle Scholar
• Weinberger MH. The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers. Am J Med 1991; 90(Suppl 5A)5A–15S
   Google Scholar
• Krishna GG, Riley LJ, Deuter G, Kapoor SC, Narins R G. Natriuretic effect of calcium-channel blockers in hypertensives. Am J Kidney Dis 1991; 18: 566–572
   PubMed Web of Science ®Google Scholar
• Luft FC, Aronoff GR, Sloan RS, Fineberg NS, Weinberger M H. Calcium channel blockade with nitrendipine: effects on sodium hoemostasiss, the renin-angiotensin system and the sympathetic nervous system in humans. Hypertension 1985; 7: 438–442
   PubMed Web of Science ®Google Scholar
• Cappuccio FP, Markandu N, Sagnella GA, Singer D RJ, Miller MA, Buckley MG, MacGregor G A. Acute and sustained changes in sodium balance during nifedipine treatment in essential hypertension. Am J Med 1991; 91: 233–238
   PubMed Web of Science ®Google Scholar
• Luft FC, Fineberg NS, Weinberger M H. Long-term effect of nifedipine and hydrochlorothiazide on blood pressure and sodium homeostasis at varying levels of salt intake in mildly hypertensive subjects. Am J Hypertens 1991; 5: 323–329
   Google Scholar
• Katzman PL, DiBona GF, Hökfelt B, Hulthen U L. Acute renal tubular and hemodynamic effects of the calcium antagonist felodipine in healthy volunteers. J Am Soc Nephrol 1991; 2: 1000–1006
   PubMed Web of Science ®Google Scholar
• Del Rio A, Rodriguez-Villamil JL, Lopez-Campos JM, Carrera F. Influencia de la restriccion salina moderada sobre la actividad antihipertensiva de la nifedipina: un estudio doble ciego. Rev Clin Esp 1990; 186: 5–10
   PubMedGoogle Scholar
• Nicholson JP, Resnick LM, Laragh J H. Hydrochlorothiazide is not additive to verapamil in treating essential hypertension. Arch intern Med 1989; 149: 125–128
   PubMed Web of Science ®Google Scholar
• Salvetti A, Magagna A, Innocenti P. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essetial hypertensives: a cross-over multicenter study. J Cardiovasc Pharmacol 1991; 17: 332–335
   PubMed Web of Science ®Google Scholar
• Di Somma Liguori S., Petitto M, Cavalloti G, Savonitto S, de Divitiis O. Hemodynamic interactions between diuretics and calcium antagonists in the treatment of hypertensive patients. Cardiovasc Drugs Ther 1990; 4: 1151–1156
   PubMed Web of Science ®Google Scholar
• Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart W H. An assessment of diltaizem and hydrochlorothiazide in hypertension. JAMA 1990; 263: 1507–1512
   PubMed Web of Science ®Google Scholar
• Luft FC, Johnston C I. Are calcium antagonists of value in ameliorating the course of chronic renal disease?. Kidney Int 1992
   Web of Science ®Google Scholar
• Bia MJ, Tyler K. Evidence that calcium channel blockade prevents cyclosporine-induced exacerbation of renal ischemic injury. Transplantation 1991; 51: 293–295
   PubMed Web of Science ®Google Scholar
• Neumayer H. H. Role of calcium antagonists in protection against acute renal failure in transplant patients. Kidney Int 1992, in press
   Google Scholar
• Dawidson I, Christopher PR, Sagalowsky A, Diller K, Palmer B, Peters P, Risser R, Sondor Z, Seney F. Verapamil improves the outcome after cadaver renal transplantation. J Amer Soc Nephrol 1991; 2: 983–990
   PubMed Web of Science ®Google Scholar
• Neumayer H., Junge W, Küfner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomized clinical trial. Nephrol Dial Transplant 1989; 4: 1030–1036
   PubMed Web of Science ®Google Scholar
• Wenzel UO, Troschau G, Schoeppe W, Helmchen U, Schwietzer G. Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992, in press
   PubMedGoogle Scholar
• Dworkin LD. Impact of calcium entry blockers on glomerular injury in experimental hypertension. Cardiovasc Drugs Ther 1990; 4: 1325–1330
   PubMed Web of Science ®Google Scholar
• Dworkin LD, Levin RI, Benstein JA, Parker M, Ullian ME, Kim Y, Feiner H D. Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 1990; 259: F598–F604
   PubMed Web of Science ®Google Scholar
• Dworkin LD, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991; 39: 1112–1117
   PubMed Web of Science ®Google Scholar
• Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension 1991; 17: 288–295
   PubMed Web of Science ®Google Scholar
• Eliahou HE, Cohen D, Hellberg B. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988; 8: 285–290
   PubMed Web of Science ®Google Scholar
• Zucchelli P, Yuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452–458
   PubMed Web of Science ®Google Scholar
• Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fauchald P, Endresen L, Djoseland O, Berg K J. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 1991; 229: 163–170
   PubMed Web of Science ®Google Scholar
• Melbourne Diabetic Nephropathy Study Group. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 1991; 302: 210–216
   PubMed Web of Science ®Google Scholar
• Block LH, Emmons L R. A new prespective on the antiatherosclerotic activity of Ca+2-channel blockers. Euro J Clin Invest 1990; 20: 236–238
   PubMed Web of Science ®Google Scholar
• Schmitz G, Hankowitz J, Kovacs E M. Cellular processes in atherogenesis: potential targets of Ca2+channel blockers. Arteriosclerosis 1991; 88: 109–132
   Google Scholar
• Hoberg E, Kübler W. Prevention of restenosis after PTCA: role of calcium antagonists. J Cardiovasc Pharmacol 1991; 18(Suppl 6)S15–S19
   PubMedGoogle Scholar
• Jost S, Rafflenbeul W, Deckers J, Wiese B, Hecker H, Nikutta P, Lippolt P, Lichtlen P. Concept of an antiatherosclerotic efficacy of calcium entry blockers. Euro J Epidemiol 1992; 8(Suppl 1)107–119
   PubMedGoogle Scholar
• Hansen JF. Calcium antagonists and myocardial infarction. Cardiovasc Drugs Ther 1991; 5: 665–670
   PubMed Web of Science ®Google Scholar
• Reicher-Reiss H, Barasch E. Calcium antagonists in patients with heart failure: a review. Drugs 1991; 42: 343–364
   PubMed Web of Science ®Google Scholar
• Murphy JJ. The role of calcium antagonists in the treatment of cerebrovascular disease. Drugs & Aging 1992; 2: 1–6
   PubMed Web of Science ®Google Scholar
• Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale G M. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysm nimodipine trial. Br Med J 1987; 295: 636–642
   PubMedGoogle Scholar
• Ernst E. Treating ischemic stroke: is nimodipine the answer? Clin Pharm 1992; 11: 350–351
   Google Scholar
• Akpunonu BE, Ahrens J D. Sexual headaches: case report, review and treatment with calcium blocker. Headache 1991; 31: 141–145
   PubMed Web of Science ®Google Scholar
• Hansson L. Calcium anatagonists: an overview. Am Heart J 1991; 122: 308–311
   PubMed Web of Science ®Google Scholar
• Messerli FH, Nunez BD, Nunez M, Garavaglia GE, Schmieder RE, Ventura H O. Hypertension and sudden death: disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmias. Arch Intern Med 1989; 149: 1263–1267
   PubMed Web of Science ®Google Scholar